RxDoctor Payments Data

Jemin Gajipara, MD

Pain Medicine · Dallas, TXNPI 1922205939

Payments from drug & device makers

$6,938in general payments, 2019–2025

Across 149 payments — averaging $46.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Curonix LLC$663
  • Collegium Pharmaceutical, Inc.$467
  • Tersera Therapeutics LLC$213
  • Protega Pharmaceutials Inc$152
  • Boston Scientific$112
  • plus $874 from 18 others

What the payments were for

  • Travel & lodging$3,32748%
  • Food & beverage$3,59052%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,938 in reported general payments places this provider in the 65th percentile of 583 pain medicine providers in Texas.

See all pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$742,149
Medicare patients
387
Services billed
28,733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nucynta ErTapentadol Hcl121$134,300
Xtampza ErOxycodone Myristate98$80,325
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,609$67,614
RoxybondOxycodone Hcl19$41,499
Buprenorphine174$32,511
BelbucaBuprenorphine Hcl34$30,066
Tramadol Hcl ErTramadol Hcl423$25,677
NucyntaTapentadol Hcl21$23,891
MovantikNaloxegol Oxalate51$21,991
Hysingla ErHydrocodone Bitartrate29$20,618
Diclofenac Sodium62$14,820
Fentanyl111$11,487
Morphine Sulfate ErMorphine Sulfate323$10,352
Buprenorphine Hcl385$9,884
Acetaminophen-CodeineAcetaminophen With Codeine312$8,261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er, Belbuca, Nucynta$467$268,582274 claims
Hikma Pharmaceuticals USABuprenorphine, Buprenorphine Hcl, Morphine Sulfate, Buprenorphine-Naloxone$21$50,326734 claims
Protega Pharmaceutials IncRoxybond$152$41,49919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 583 pain medicine providers in Texas.

Other pain medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →